Question explored with the scientific record
What human or animal mRNA vaccines are used in Canada
The short version: Canada uses two human mRNA COVID-19 vaccines, Pfizer and Moderna. No mRNA vaccine is licensed for animals in Canada.
The human ones are Pfizer-BioNTech's BNT162b2 and Moderna's mRNA-1273, both lipid-nanoparticle COVID-19 shots [1][5]. The retrieved records describe them as authorized and used, including in Canadian cohorts [2][3]. That is the whole of the human mRNA vaccine list these records support.
For animals, the records show mRNA vaccines only in research and preclinical settings, not as licensed Canadian products. There are mRNA rabies candidates tested in dogs and other species [4], a pig vaccine against porcine deltacoronavirus [6], a duck vaccine against Tembusu virus [7], and a dog cancer immunotherapy [8]. None of these records places any of them in Canadian veterinary use.
| Vaccine | Species | Status in these records |
|---|---|---|
| BNT162b2 (Pfizer) | Human | In use, including Canada [1][2] |
| mRNA-1273 (Moderna) | Human | In use, including Canada [2][3] |
| LVRNA001 (rabies) | Dog, rodent, macaque | Preclinical only [4] |
| PDCoV spike mRNA | Pig | Research only [6] |
| DTMUV mRNA | Duck | Research only [7] |
This retrieval cannot see Health Canada's actual authorization list or provincial formularies. It shows what the studies describe, not the current regulatory register. If you need the definitive licensed-product list, that is a Health Canada database question, not a literature question.
My call: two human mRNA vaccines are in Canadian use, and no animal mRNA vaccine is licensed here based on what these records show. Confidence: moderate on the human list, low on the animal list, because the retrieval does not include the regulatory register itself.
Sources used 8
-
Comparing the Efficacy and Safety of the Pfizer BNT162b2 Vaccine with Other Alternatives Under COVID-19
A comparative analysis of the efficacy and safety of the Pfizer-BNT162b2 mRNA vaccine versus Novavax NVX-CoV2373 and Sinovac-CoronaVac across multiple SARS-CoV-2 variants, highlighting differences in vaccine effectiveness and adverse event profiles from randomized trials and rea…
DOI: 10.54097/4dy5rk83 -
Assessing the incidence of myocarditis risk in mRNA COVID-19 vaccines: a systematic review and meta-analysis
A systematic review and meta-analysis comparing myocarditis risk after Moderna (mRNA-1273) versus Pfizer-BNT162b2 vaccines across doses and populations, finding a non-significant trend toward higher risk with Moderna and myocarditis to be overall uncommon.
DOI: 10.61505/evidence.2024.2.1.27 -
Effectiveness of a single COVID-19 mRNA vaccine dose in individuals with prior SARS-CoV-2 infection: a systematic review
A systematic review of 18 studies (over 5.8 million participants) showing that a single dose of original mRNA COVID-19 vaccine provides meaningful additional protection for individuals with prior SARS-CoV-2 infection, often comparable to or greater than two-dose regimens with pr…
DOI: 10.1038/s43856-025-00882-y -
Safety and efficacy assessment of an mRNA rabies vaccine in dogs, rodents, and cynomolgus macaques
An mRNA vaccine encoding the rabies virus glycoprotein (LVRNA001) delivered with lipid nanoparticles provides cross-strain protection against rabies in dogs and mice, elicits robust humoral and Th1-biased T cell responses in cynomolgus macaques, and shows favorable chronic and r…
DOI: 10.1038/s41541-024-00925-w -
Research progress of mRNA vaccines for infectious diseases
A comprehensive scoping review of mRNA vaccine technology for infectious diseases, detailing their structural elements, delivery systems, immune mechanisms, clinical progress across multiple pathogens, and the challenges ahead, with TB-focused considerations.
DOI: 10.1186/s40001-025-03060-x -
A spike-based mRNA vaccine that induces durable and broad protection against porcine deltacoronavirus in piglets
A spike-based PDCoV mRNA-LNP vaccine induces durable humoral and cellular immunity in mice and provides durable passive protection against PDCoV in suckling piglets, outperforming an inactivated vaccine.
DOI: 10.1128/jvi.00535-24 -
An mRNA vaccine provides effective protection against Duck Tembusu Virus infection
This study demonstrates the development and efficacy of a novel mRNA vaccine against Duck Tembusu Virus (DTMUV), which provides complete protection in ducks and shows potential for maternal antibody transfer.
DOI: 10.1038/s41541-025-01146-5 -
Immunomodulatory vaccine demonstrates therapeutic efficacy across cancer types
A multitarget immunomodulatory mRNA-LNP vaccine targeting CCL22, TGF-β, CTLA-4, Galectin-3, PD-L1, IDO1, and ARG1 was administered to eight dogs with spontaneous cancers, showing good tolerability and a 75% disease control rate (SD or better) with durable progression-free surviv…
DOI: 10.1038/s41598-025-21924-4